Characterization of a new BALL cell line with constitutional defect of the Notch signaling pathway

Notch signaling contribution to B-cell acute lymphoblastic leukemia (B-ALL) development is still under investigation. The serendipitous onset of B-ALL in a patient affected by the germinal Notch mutation-dependent Alagille syndrome allowed us to establish a B-ALL cell line (VR-ALL) bearing a genetic loss of function in components of Notch signaling. VR-ALL is a common-type B-ALL cell line, grows in conventional culture medium supplemented with 10% serum, and gives rise, once injected into immunodeficient NOG mice, to a mouse xenograft model of B-ALL. Exome sequencing revealed deleterious mutations in some components of Notch signaling, including Jagged1, Notch1, and Notch2. In addition, VR-ALL is sensitive both in vitro and in vivo to γ-secretase inhibitors (GSIs) as well as conventional anti-leukemic drugs. For all these reasons, VR-ALL may help to gain more insights into the role of Notch signaling in B-ALL. www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 26), pp: 18341-18350

[1]  W. Chung,et al.  Deep Genetic Connection Between Cancer and Developmental Disorders , 2016, Human mutation.

[2]  M. Krampera,et al.  Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia , 2016, Oncotarget.

[3]  H. Cavé,et al.  Acute lymphoblastic leukemia in the context of RASopathies. , 2016, European journal of medical genetics.

[4]  Yoichi Matsubara,et al.  Recent advances in RASopathies , 2015, Journal of Human Genetics.

[5]  Laura M. Heiser,et al.  Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics , 2015, Molecular Cancer Research.

[6]  C. Récher,et al.  A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia , 2015, Blood Cancer Journal.

[7]  C. Mullighan.  The genomic landscape of acute lymphoblastic leukemia in children and young adults. , 2014, Hematology. American Society of Hematology. Education Program.

[8]  J. Sage,et al.  From fly wings to targeted cancer therapies: a centennial for notch signaling. , 2014, Cancer cell.

[9]  T. Golde,et al.  γ-Secretase inhibitors and modulators. , 2013, Biochimica et biophysica acta.

[10]  R. Gniadecki,et al.  Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ‐secretase inhibitor I in cutaneous T‐cell lymphoma , 2013, The British journal of dermatology.

[11]  Hideki Uosaki,et al.  Non-canonical Notch signaling: emerging role and mechanism. , 2012, Trends in cell biology.

[12]  A. Ferrando,et al.  Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia , 2012, Molecular Cancer Therapeutics.

[13]  I. Krantz,et al.  NOTCH2 mutations in Alagille syndrome , 2011, Journal of Medical Genetics.

[14]  G. Pizzolo,et al.  Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. , 2011, Blood.

[15]  T. Mazel,et al.  GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia , 2011, Leukemia.

[16]  B. Ezquieta,et al.  Myeloproliferative Disorder in Noonan Syndrome , 2011, Journal of pediatric hematology/oncology.

[17]  D. Haber,et al.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents , 2010, Nature Reviews Cancer.

[18]  H. Hasle.  Malignant Diseases in Noonan Syndrome and Related Disorders , 2009, Hormone Research in Paediatrics.

[19]  Jing Chen,et al.  ToppGene Suite for gene list enrichment analysis and candidate gene prioritization , 2009, Nucleic Acids Res..

[20]  V. Detours,et al.  Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells? , 2009, Biochimica et biophysica acta.

[21]  J. McCarthy,et al.  Presenilin-dependent regulated intramembrane proteolysis and γ-secretase activity , 2009, Cellular and Molecular Life Sciences.

[22]  S. Blacklow,et al.  The molecular logic of Notch signaling – a structural and biochemical perspective , 2008, Journal of Cell Science.

[23]  Bart De Moor,et al.  Endeavour update: a web resource for gene prioritization in multiple species , 2008, Nucleic Acids Res..

[24]  N. Yoo,et al.  Mutational analysis of NOTCH1, 2, 3 and 4 genes in common solid cancers and acute leukemias , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[25]  D. Curtis,et al.  Presenilin diversifies its portfolio. , 2007, Trends in genetics : TIG.

[26]  Martin J Firth,et al.  Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines , 2006, British Journal of Cancer.

[27]  I. Krantz,et al.  NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. , 2006, American journal of human genetics.

[28]  L. Gibson,et al.  Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. , 2000, Blood.

[29]  Colin C. Collins,et al.  Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1 , 1997, Nature Genetics.

[30]  T. Hongo,et al.  In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. , 1997, Blood.

[31]  C. Guerra,et al.  Modeling RASopathies with Genetically Modified Mouse Models. , 2017, Methods in molecular biology.

[32]  D. Kovacs,et al.  The many substrates of presenilin/γ-secretase. , 2011, Journal of Alzheimer's disease : JAD.

[33]  Iannis Aifantis,et al.  γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia , 2009, Nature Medicine.

[34]  Hong Sun,et al.  Analysis of transformation and tumorigenicity using mouse embryonic fibroblast cells. , 2007, Methods in molecular biology.

[35]  S. Korsmeyer,et al.  Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. , 1985, Blood.